March 13, 2026
1 min read

‘Manufacturing is access’: How Gilead’s early production moves set PrEP med Yeztugo up for success

From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. And, for the twice-yearly pre-exposure prophylaxis medication—which Gilead Sciences has positioned as a key tool in the fight to end the HIV epidemic—“manufacturing is access.”

Leave a Reply

Your email address will not be published.

Previous Story

Feeling tired, achy, or weak? Expert says low vitamin D could be the cause, here’s how sunlight, nutrition, and doctor-guided supplements can help

Next Story

Younger Stroke Survivors Face Unique Mental Health Hurdles MedNews

Previous Story

Feeling tired, achy, or weak? Expert says low vitamin D could be the cause, here’s how sunlight, nutrition, and doctor-guided supplements can help

Next Story

Younger Stroke Survivors Face Unique Mental Health Hurdles MedNews

Latest from Blog

Go toTop